No Detail Found!

Pathologic Complete Response in Her2-positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.

Author(s)
Fareeha Sheikh Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
Adil Nazir Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
Samia Yasmeen Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
Farhana Badar Department of Biostatistics and Epidemiology, Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
Usman Ahmad Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
Neelam Siddiqui Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital, Lahore, Pakistan
Abstract
Objective: To compare the pathological complete response in human epidermal growth factor receptor type 2 (HER-2) positive breast cancer patients getting neoadjuvant chemotherapy with or without trastuzumab. Study Design: Retrospective randomised double-arm observational study. Place and Duration of Study: Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, from 2008 to 2016. Methodology: HER2-positive, lymph node positive, breast cancer patients receiving neoadjuvant chemotherapy (NACT) were retrospectively observed. Patients getting neoadjuvant trastuzumab, fulfilling the inclusion criteria were studied. The comparison group included randomly selected equal number of HER2-positive breast cancer patients having similar tumor characteristics, getting NACT only. Pathological complete response (pCR) was defined as no residual invasive or in situ residual tumor in breast tissue, or in the lymph nodes. One hundred and fifty-six patients were studied. Eighty-nine patients with HER2-positive disease received trastuzumab preoperatively. Sixty-four (n=64) patients received the complete standard dose of neoadjuvant trastuzumab along with chemotherapy. Almost equal number of patients (n=67) with HER2positive disease were selected by random assortment for the reference group who did not receive trastuzumab before surgery. Results: The pathological complete response of study group was (n=32) 50%, which was 26.1% higher than the reference group (n=16) 23.9%; and this difference was statistically significant with a p-value of 0.002 (<0.05). The overall pCR was 36.6% (n=48). Conclusion: Addition of trastuzumab to neoadjuvant chemotherapy doubled the pCR in HER2-positive breast cancer. Targeted therapy should be offered to all eligible patients with HER2-overexpressing breast cancer.
Publication Details
Page(s) 159-163
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 29, Issue: 2, Year: 2019

Request the full text from PASTIC

References
BursteinHJ, 2005.The distinctive nature of HER2-positive breast cancers,New Engl J Med 353 1652 -4
MitriZ,ConstantineT,O'Regan R. The, 2012.HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy,Chemother Res Pract 743193 -
AndersonWF,RosenbergPS,KatkiHA, dju093.Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer,J Natl Cancer Inst Monogr 106 -
CuriglianoG,VialeG,BagnardiV,FumagalliL,LocatelliM,RotmenszN, 2009.Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer,J Clin Oncol 27 5693 -9
Gonzalez-AnguloAM,LittonJK,BroglioKR,Meric-BernstamF,RakkhitR,CardosoF, 2009.High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller,J Clin Oncol 27 5700 -6
RouanetP,RogerP,RousseauE,ThibaultS,RomieuG,MathieuA, 2014.HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort,Cancer Med 3 134 -42
FerrettiG,FeliciA,PapaldoP,FabiA,CognettiF., 2007.HER2/neu role in breast cancer: From a prognostic foe to a predictive friend,Cur Opin Obstet Gynecol 19 56 -62
PerezEA,RomondEH,SumanVJ,JeongJH,SledgeG,Geyer JrCE,NCCTGN9831. J Clini, 2014.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31, 32 3744 -52
BuzdarAU,IbrahimNK,FrancisD,BooserDJ,ThomasES,TheriaultRL, 2005.Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer,J Clin Oncol 23 3676 -85
GianniL,EiermannW,SemiglazovV,LluchA,TjulandinS,ZambettiM, 2014.Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort,Lancet Oncol 15 640 -7
BroglioKR,QuintanaM,FosterM,OlingerM,McGlothlinA,BerrySM, 2016.Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis,JAMA Oncol 2 751 -60
SpringL,GreenupR,ReynoldsK,SmithBL,MoyB,BardiaA, 2016.Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients. 2016 AACR Annual Meeting,Abstract presented April 18 -
ProwellTM,PazdurR, 2012.Pathological complete response and accelerated drug approval in early breast cancer,New Engl J Med 366 2438 -41
CortazarP,ZhangL,UntchM,MehtaK,CostantinoJP,WolmarkN, 2014.Pathological complete response and longterm clinical benefit in breast cancer: the CTNeoBC pooled analysis,Lancet 384 164 -72
UntchM,RezaiM,LoiblS,FaschingPA,HuoberJ,TeschH, 2010.Neoadjuvant treatment with trastuzumab in HER2- positive breast cancer: Results from the GeparQuattro study,J Clin Oncol 28 2024 -31
UntchM,FaschingPA,KonecnyGE,HasmüllerS,LebeauA,KreienbergR, 2011.Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups,J Clin Oncol 29 3351 -7
GianniL,EiermannW,SemiglazovV,ManikhasA,LluchA,TjulandinS, 2010.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2- positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2- negative cohort,Lancet 375 377 -84
ZeeshanS,KhanSM,KhanN., 2016.Pathologic tumor response and long term outcome with neoadjuvant trastuzumab in Her-2 positive breast cancer,Ann Oncol 27 006 -
GajriaD,ChandarlapatyS., 2011.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies,Expert Rev Anticancer Ther 11 263 -75
SternHM,GardnerH,BurzykowskiT,ElatreW,O'BrienC,LacknerMR, 2015.PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance,Clin Cancer Res 21 2065 -74
0

Citations

0

Downloads

99

Views